KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study. PMID 41757470 · Cancer Res Commun · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Histopathologic growth patterns as prognostic factor for survival in patients with colorectal liver metastases. PMID 41686533 · Radiol Oncol · 2026-Mar-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial. PMID 41637102 · JAMA Cardiol · 2026-Mar-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial. PMID 41634905 · Am J Psychiatry · 2026-Mar-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial. PMID 41609798 · JAMA Oncol · 2026-Mar-01 This is a secondary analysis of cancer outcomes from the ASPREE trial, which was primarily a cardiovascular prevention trial in older adults. While randomized and drug-interventional (aspirin), it is not a primary report of a Phase III/IIIb or Phase II/III oncology trial, and the reported endpoints are secondary analyses of cancer incidence and mortality, not a primary/key secondary efficacy endpoint for an anticancer drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. PMID 41609753 · JAMA Oncol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial. PMID 41547249 · Int Immunopharmacol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy. PMID 41533467 · Clin J Am Soc Nephrol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of a Phase III Cardiac Rehabilitation Program on Physical Exercise in Patients with Ischemic Heart Disease: A Cluster Randomized Controlled Trial. PMID 41529161 · J Cardiopulm Rehabil Prev · 2026-Mar-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Updates in tolerance: future directions to improve kidney allograft survival. PMID 41527400 · Curr Opin Nephrol Hypertens · 2026-Mar-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Dexmedetomidine nasal spray for acute agitation in adults with bipolar disorder: a single-arm open-label trial. PMID 41360383 · J Affect Disord · 2026-Mar-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1. PMID 41343248 · Clin J Am Soc Nephrol · 2026-Mar-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. PMID 41274280 · Inflamm Bowel Dis · 2026-Mar-01 Study is not an oncology trial; it evaluates a drug (ozanimod) for ulcerative colitis (inflammatory bowel disease). While it is a Phase III randomized trial with a drug intervention and original results, it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and focuses on safety and clinical/mucosal efficacy rates, not Kaplan-Meier or time-to-event outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial. PMID 41270788 · J Natl Cancer Inst · 2026-Mar-01 The report is a randomized trial in human oncology with a drug intervention, but its primary analysis is focused on health-related quality of life, not a time-to-event efficacy endpoint. The time-to-event outcome (PFS) is mentioned in the background as part of the parent trial's results, but this specific report's methodology and results are dedicated to QoL assessment using patient-reported outcomes, not Kaplan-Meier or HR analysis. Therefore, it does not meet the time-to-event requirement.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease. PMID 41189093 · Inflamm Bowel Dis · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials. PMID 41129125 · J Acquir Immune Defic Syndr · 2026-Mar-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology. PMID 41035401 · Haematologica · 2026-Mar-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized Trial. PMID 41027544 · Int J Radiat Oncol Biol Phys · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial. PMID 40694062 · Int Clin Psychopharmacol · 2026-Mar-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study. PMID 40662488 · Int Clin Psychopharmacol · 2026-Mar-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fecal Immunochemical Test Completion by Instruction Type: A Randomized Clinical Trial Comparing Quick Response Code-Linked Video to Pictorial Instructions. PMID 40622392 · Am J Gastroenterol · 2026-Mar-01 The record describes a randomized quality improvement study comparing instruction methods for fecal immunochemical test (FIT) completion in colorectal cancer screening. While oncology and human criteria are met, and it is randomized, it lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). The study is also not Phase III or II/III. Thus, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis. PMID 40531526 · Am J Gastroenterol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial. PMID 40384092 · Hepatology · 2026-Mar-01 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Role of Preoperative Tapentadol in Reduction of Peri-operative Analgesics Requirements After Breast Conservative Surgery in Cancer Patients: A Randomized Controlled Trial. PMID 42394994 · J Cancer Allied Spec · 2026-Mar The study is a randomized, controlled trial involving a drug in an oncology (breast cancer) population, but it is an analgesia/safety study focused on perioperative pain management, not an efficacy trial for a cancer treatment with a time-to-event endpoint. Furthermore, the trial phase is not specified, so it cannot be confirmed as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study. PMID 42370118 · EULAR Rheumatol Open · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty. PMID 42051839 · Cureus · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol. PMID 42022357 · Precis Radiat Oncol · 2026-Mar 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Analysis of depressive symptom trajectory patterns with zuranolone: Time-series clustering of Japanese Phase 2 and Phase 3 trial data. PMID 42022339 · PCN Rep · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113). PMID 41994030 · ESMO Gastrointest Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial. PMID 41938843 · EClinicalMedicine · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial. PMID 41937811 · JCO Oncol Adv · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis. PMID 41930050 · Cureus · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Diet and Physical Activity Interventions to Improve Outcomes in Colorectal Cancer Survivors: A Multicenter Randomized Controlled Trial in North Africa. PMID 41886719 · JCO Glob Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
An evaluation of cytisinicline for smoking cessation in adult smokers. PMID 41885781 · Expert Opin Pharmacother · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study). PMID 41884323 · Cureus · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-Term Survival Outcomes of Concurrent Chemoradiotherapy for Postoperative High-Risk Salivary Gland Carcinomas. PMID 41878954 · Cancer Med · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer. PMID 41866301 · Psychooncology · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial. PMID 41853747 · ESMO Gastrointest Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Use of DOOR and Win-Ratio Analysis in a Secondary Evaluation of a Histoplasmosis Clinical Trial. PMID 41852554 · Open Forum Infect Dis · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study. PMID 41852303 · Cancer Med · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis. PMID 41846682 · ERJ Open Res · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Exercise on Cognitive Impairment in Patients Receiving Chemotherapy: A Multicenter Phase III Randomized Controlled Trial. PMID 41825129 · J Natl Compr Canc Netw · 2026-Mar The study is an eligible Phase III randomized trial with drug-containing context (chemotherapy), but it fails the time-to-event endpoint criterion. The primary outcomes are cognitive impairment and mental fatigue scores, which are continuous patient-reported outcomes, not time-to-event events (like survival or progression). No Kaplan-Meier curves, hazard ratios, or time-to-event endpoints are mentioned.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing Clinical Characteristics and Outcomes of Tenecteplase Versus Alteplase in Young Adult Patients With Stroke: A Secondary Analysis of the AcT Trial. PMID 41815318 · Stroke Vasc Interv Neurol · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Secondary cytoreductive surgery (S-CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent ovarian cancer: Current evidence and clinical perspectives. PMID 41813375 · Taiwan J Obstet Gynecol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial. PMID 41812092 · JCO Glob Oncol · 2026-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Multicentre dosimetry audit in the European randomized phase III study of neoadjuvant chemoradiotherapy using proton versus photon radiotherapy in locally advanced oesophageal cancer. PMID 41810037 · Phys Imaging Radiat Oncol · 2026-Mar The record is an abstract for a dosimetry audit (technical quality assurance) within a randomized phase III oncology trial. While the parent trial (PROTECT) is oncologic, human, randomized, and phase III, this specific abstract reports only on radiation dose measurement verification, not on any clinical efficacy endpoint (e.g., OS, PFS). Furthermore, the intervention compared is proton versus photon radiotherapy (non-drug), and the abstract does not present the primary trial results. Therefore, it is ineligible.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial. PMID 41808691 · Lancet Reg Health Southeast Asia · 2026-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Influence of Hospital and Surgeon Volumes on Clinical Outcomes After Standard Surgery for Advanced Gastric Cancer: Supplementary Analysis of the Multicenter Randomized Phase III Trial JCOG1001. PMID 41799591 · Ann Gastroenterol Surg · 2026-Mar This is a supplementary analysis of a phase III randomized trial (JCOG1001) that compares surgical techniques (standard vs. experimental surgery) for gastric cancer. The intervention is surgical, not drug-containing. Therefore, it does not meet the inclusion criterion of a drug-containing intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT. PMID 41797548 · Health Technol Assess · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential? PMID 41797519 · Expert Opin Investig Drugs · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -